This study focuses on treating adenovirus infection in patients who have received a stem cell transplant. Adenovirus is a virus that can cause serious complications in people with weakened immune systems, particularly after transplantation procedures. The study compares two medications: brincidofovir and cidofovir, both given through an intravenous infusion (delivery of medication through a vein).
The purpose of this research is to determine how well brincidofovir works compared to cidofovir in treating adenovirus infection in both children and adults who have received a transplant. Both medications are designed to fight viral infections, but they work in slightly different ways. The study will evaluate which treatment is more effective at eliminating the virus from the blood.
During the study, participants will receive either brincidofovir or cidofovir through intravenous infusion. The treatment period may last up to 12 weeks, during which doctors will monitor how well the medications work and check for any side effects. The study team will track various aspects of the participants’ health, including how quickly the virus levels decrease and how long patients need to stay in the hospital.
France 
Germany 
Italy 
Spain 
